MedTrace Logo

Sport Therapy and Osteopathy Manipulative Treatment in ALS

NCT02548663 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-09-15

No results posted yet for this study

Summary

This project assessed muscle oxidative metabolism and fatigue in patients affected by amyotrophic lateral sclerosis (ALS) undergoing to three months of individualized cardiovascular and strength training. Muscle oxidative metabolism and strength will be assessed by non-invasive methods, such as near-infrared spectroscopy (NIRS) and mechanomyography (MMG). NIRS is a technique giving indications on the capacity of oxygen extraction of muscles during exercise. MMG allows analyzing the pattern of motor unit recruitment and related fatigue. The investigators will also assess the effects of training on pain tolerance and quality of life (QoL) by the Brief Pain Inventory and the McGill Quality of Life questionnaires, using the validated Italian versions. Patients will be assessed longitudinally before (time T0) and after three months of individualized training (time T1). After one month of de-training (time T2) the investigators will assess the hypothetic persistence of any treatment-related effect. The effect of three months-osteopathic treatment (osteo) on pain and QoL will be assessed as well.

Conditions

Interventions

OTHER

Sport therapy

Frequency: 60 min three times/week 1. 20 min: aerobic training on bicycle ergometer. 2. 20 min: strength training at 60% of maximal load. 3. 20 min: proprioception and stretching exercises.

OTHER

Osteopathic treatment

Frequency: 60 min weekly

Sponsors & Collaborators

  • Italian Academy of Osteopathic Medicine (AIMO), Saronno, Italy

    collaborator UNKNOWN

  • University of Milano Bicocca

    lead OTHER

Principal Investigators

  • Francesca Lanfranconi, MD · University of Milano Bicocca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-12-31
Completion
2015-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02548663 on ClinicalTrials.gov